Cellectis S.A. (CMVLF)
| Market Cap | 110.88M |
| Revenue (ttm) | 54.75M |
| Net Income (ttm) | -60.53M |
| Shares Out | n/a |
| EPS (ttm) | -0.62 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 400 |
| Average Volume | 424 |
| Open | 1.250 |
| Previous Close | n/a |
| Day's Range | 1.250 - 1.250 |
| 52-Week Range | 1.250 - 1.500 |
| Beta | 3.28 |
| RSI | 31.57 |
| Earnings Date | Aug 4, 2025 |
About Cellectis
Cellectis S.A., a clinical stage biotechnological company, develops products based on gene-editing with a portfolio of allogeneic chimeric antigen receptor T-cells product candidates. The company is developing ALLO-501 to treat large B-cell lymphoma; ALLO-316, an allogeneic engineered CAR T-cell product targeting CD70; ALLO-819 to treat acute myeloid leukemia; ALLO-213 for the treatment of small cell lung cancer; and ALLO-182 to treat gastric and pancreatic cancer. It also develops UCART22 for the treatment of relapsed or refractory B-cell acut... [Read more]
Financial Performance
In 2024, Cellectis's revenue was $49.22 million, an increase of 435.37% compared to the previous year's $9.19 million. Losses were -$36.76 million, -63.62% less than in 2023.
Financial StatementsNews
Cellectis' Annual Shareholders General Meeting to be Held on June 26, 2025
NEW YORK, May 21, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to devel...
Cellectis: Partnerships And Promised Data In 2025 Continue To Justify The Buy
Discover Cellectis SA's innovative CAR T-cell therapies targeting heme malignancies & upcoming 2025 catalysts.
Cellectis Non-GAAP EPS of -$0.17, revenue of $12M misses by $1.83M
Cellectis Reports Financial Results for the First Quarter 2025
NEW YORK, May 12, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to devel...
Cellectis Q1 2025 Earnings Preview
Cellectis to Report First Quarter Financial Results on May 12, 2025
NEW YORK, May 06, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develo...
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to dev...
Cellectis S.A. (CLLS) Q4 2024 Earnings Call Transcript
Cellectis S.A. (NASDAQ:CLLS) Q4 2024 Earnings Conference Call March 14, 2025 8:00 AM ET Company Participants Arthur Stril - CFO and Chief Business Officer Andre Choulika - CEO Adrian Kilcoyne - CMO C...
Cellectis Reports Financial Results for the Fourth Quarter and Full Year 2024 and Provides a Business Update
○ UCART22 Phase 1 dataset and late-stage development strategy expected in the third quarter of 2025; Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) granted by FDA and ODD ...
Cellectis to Report Fourth Quarter and Full Year 2024 Financial Results on March 13, 2025
NEW YORK, March 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...
Cellectis Presents ‘Smart CAR T' Strategy to Enhance Efficacy Against Solid Tumors at AACR-IO 2025
NEW YORK, Feb. 24, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...
Cellectis: Poised To Start Answering Questions In 2025
Cellectis S.A.'s pipeline updates highlight promising advancements in engineered, allogeneic cell therapies. The financial overview indicates a strong cash position, but ongoing R&D expenses pose a ri...
Cellectis announces the drawdown of the third tranche of €5 million under the credit facility agreement entered with the European Investment Bank (EIB)
NEW YORK, Dec. 10, 2024 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth: ALCLS – NASDAQ: CLLS) (the “Company”), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...
Cellectis Presents Multiple Strategies to Enhance CAR T-cell Efficacy in Solid Tumors at the SITC Annual Meeting
NEW YORK, Nov. 05, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to dev...
Cellectis S.A. (CLLS) Q3 2024 Earnings Call Transcript
Cellectis S.A. (NASDAQ:CLLS) Q3 2024 Earnings Conference Call November 5, 2024 8:00 AM ET Company Participants Arthur Stril - Interim Chief Financial Officer Andre Choulika - Chief Executive Officer ...
Cellectis Provides Business Updates and Financial Results for Third Quarter 2024
NEW YORK, Nov. 04, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to deve...
Cellectis to Report Third Quarter 2024 Financial Results on November 4, 2024
NEW YORK, Oct. 30, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS- NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...
Cellectis to Present Data on TALE-Base Editors and Non-Viral Gene Therapy at the ESGCT 31st Annual Congress
NEW YORK, Oct. 22, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...
Cellectis Presents Pre-Clinical Evidence of MUC1 CAR T-cells Reducing Triple-Negative Breast Cancer While Preserving Safety
NEW YORK, Sept. 03, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to dev...
Cellectis: Cheap With Promising But Speculative Cancer Therapies
Cellectis S.A. leverages its UCART platform and TALEN gene-editing technology to develop innovative, off-the-shelf CAR-T therapies for cancer treatment. UCART22, a key candidate in Cellectis's pipelin...
Cellectis Publishes a Molecular Therapy Article on a SMART DUAL CAR T-cell Approach for Treating Recalcitrant Solid Tumors
NEW YORK, Aug. 26, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...
Cellectis Appoints Dr. Adrian Kilcoyne as Chief Medical Officer
NEW YORK, Aug. 07, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to deve...
Cellectis Provides Financial Results for the Second Quarter 2024
NEW YORK, Aug. 06, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to deve...
FDA Grants Orphan Drug Designation to Cellectis' CLLS52 (alemtuzumab) For ALL Treatment
NEW YORK, Aug. 01, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to dev...
FDA Grants Orphan Drug and Rare Pediatric Disease Designation Status to Cellectis' UCART22 product candidate for Acute Lymphoblastic Leukemia (ALL) Treatment
NEW YORK, July 25, 2024 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to dev...